Brind.

AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application.

5 reports, 2 independent Updated Sep 12
Gone quiet
Reports
5
Developments
2
Repetition
80%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application.

Who's involved

What this event is mainly about
AxoGenFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. AxoGen, a Florida-based company, announced on July 3rd that it invested in Avance and presented at a Goldman Sachs conference.Sub-event
  2. FDA extended the BLA review date for AxoGen's Avance Nerve Graft.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • finanznachrichten.de
  • BenzingaFDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (N
3 more outlets ran the same wire story